Product NDC: | 58406-435 |
Proprietary Name: | ENBREL |
Non Proprietary Name: | etanercept |
Active Ingredient(s): | 50 mg/mL & nbsp; etanercept |
Administration Route(s): | SUBCUTANEOUS |
Dosage Form(s): | SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 58406-435 |
Labeler Name: | Immunex Corporation |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | BLA103795 |
Marketing Category: | BLA |
Start Marketing Date: | 20051006 |
Package NDC: | 58406-435-04 |
Package Description: | 4 SYRINGE in 1 CARTON (58406-435-04) > 1 mL in 1 SYRINGE (58406-435-01) |
NDC Code | 58406-435-04 |
Proprietary Name | ENBREL |
Package Description | 4 SYRINGE in 1 CARTON (58406-435-04) > 1 mL in 1 SYRINGE (58406-435-01) |
Product NDC | 58406-435 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | etanercept |
Dosage Form Name | SOLUTION |
Route Name | SUBCUTANEOUS |
Start Marketing Date | 20051006 |
Marketing Category Name | BLA |
Labeler Name | Immunex Corporation |
Substance Name | ETANERCEPT |
Strength Number | 50 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Tumor Necrosis Factor Blocker [EPC],Tumor Necrosis Factor Receptor Blocking Activity [MoA] |